PIK3CA and cervical carcinoma: Specifically, CaSki cells showed ~30% survival at 2 μM cisplatin, compared to ~3% and ~1% in SiHa and HeLa respectively, suggesting that expression of PIK3CA-E545K may confer resistance to cisplatin in cervical cancer cells.